Study identifies mechanism by which glioblastoma-derived vesicles impair cognition after radiation treatment
Researchers found that extracellular vesicles released from glioblastoma tumors after radiation therapy trigger cognitive impairment through activation of the NFκB pathway in immune cells of the brain. The study demonstrates that these vesicles cause oxidative stress and neuroinflammation in animal models and cell cultures. The findings suggest targeting this mechanism could help prevent cognitive decline in glioblastoma survivors.
A new preprint study published on bioRxiv reveals that glioblastoma-derived extracellular vesicles (EVs) released following radiation treatment promote cognitive impairment through NFκB-mediated microglial activation. Researchers conducted both in vivo experiments in animal models and in vitro cell culture studies, finding that radiation-triggered EVs (RT-EVs) induced cognitive deficits and neuroinflammatory responses. The mechanistic work showed that RT-EVs activate the NFκB signaling pathway, leading to the release of neurotoxic hydrogen peroxide, with NFκB p50 knockdown experiments confirming this pathway's necessity. The study identifies EV-driven redox dysregulation as a potential therapeutic target for mitigating cognitive dysfunction associated with glioblastoma and its treatment.
What's missing
The study is a preprint and has not undergone peer review. The authors do not discuss potential clinical translation timelines, whether findings in animal models translate to humans, or whether existing therapeutic approaches targeting NFκB could be repurposed for this indication.
What different sources said
- bioRxivCenter
Glioblastoma-derived extracellular vesicles released after radiation promote cognitive impairment through NFκB-mediated microglial activation
Related
Study Identifies Galectin-3's Role in Gastric Metaplasia Development Through Cathartocytosis
Researchers found that galectin-3, a protein upregulated in precancerous tissue changes, facilitates a cellular process called cathartocytosis that promotes the development of spasmolytic polypeptide expressing metaplasia (SPEM) in the stomach. Galectin-3 is abnormally expressed alongside sulfated mucins in high-risk precancerous conditions like Barrett's esophagus and intestinal metaplasia. The findings suggest galectin-3 may represent a therapeutic target for preventing progression from normal tissue to metaplastic and potentially cancerous states.
Study reveals spermatogonial stem cell clones don't follow random drift patterns in zebrafish
Researchers used CRISPR barcoding to track how spermatogonial stem cells (SSCs) contribute to sperm production across a zebrafish's lifetime, finding that clonal dynamics deviate significantly from neutral drift models. The study developed a mathematical framework showing that larger clones tend to drift at higher rates, suggesting non-random selection pressures. These findings have implications for understanding allele transmission and male fertility across the reproductive lifespan.
Researchers identify synthetic lethal TYMS inhibitor effective against ATRX-deficient cells
Scientists developed a phenotype-first screening approach that identified PP12, a covalent fragment that selectively kills ATRX-deficient cells by inhibiting thymidylate synthase (TYMS). The study combines covalent fragment screening, chemoproteomics, and genetic analysis to link drug phenotypes to specific cellular targets. This work establishes a generalizable methodology for discovering synthetic lethal drug candidates in cancer cells with specific genetic deficiencies.